A look at Charcot-Marie-Tooth disease

Authors

  • Hernán Cortés Callejas Laboratorio de Medicina Genómica, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación.
  • Jonathan Javier Magaña Aguirre Laboratorio de Medicina Genómica, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación.
  • Óscar Hernández Hernández Laboratorio de Medicina Genómica, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación.
  • José Arturo Ávalos Fuentes Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del IPN.
  • Sergio Recillas Morales Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del IPN.
  • Norberto Leyva García Laboratorio de Medicina Genómica, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación.

Keywords:

Charcot-Marie- Tooth disease, peripheral neuropathies, molecular diagnostic, genetic counseling

Abstract

Charcot-Marie-Tooth disease (CMT) is a group of common inherited neuropathies that affects

the peripheral nervous system. The CMT has an important place among peripheral neuropa-
thies, it is the most frequent in the world and its prevalence has been estimated in 1-2,500

people. The transmission of this neuropathy can be autosomal dominant, autosomal recessive
or chromosome X-linked types. The CMT classification is performed on the basis of clinical

criteria, electrophysiological, anatomopathological and genetic characteristics. A clinical vari-
ability and genetic heterogeneity is shown by the distinct CMT subtypes. The knowledge about

the CMT pathogenesis has increased in the last years and, with the improvement in techniques
of molecular biology, the discovery of more than 30 genes and loci associated to CMT has
been possible. Given the hereditary nature of this neuropathy, correct diagnosis is of pivotal
importance in order to give patients a suitable genetic counseling. Remarkably, novel animal
models recently developed, reproducing clinical and genetic features of CMT, can be useful
to create new therapies for the treatment of this disease, which unfortunately has no cure.

Publication Facts

Metric
This article
Other articles
Peer reviewers 
0
2.4

Reviewer profiles  N/A

Author statements

Author statements
This article
Other articles
Data availability 
N/A
16%
External funding 
N/A
32%
Competing interests 
No
11%
Metric
This journal
Other journals
Articles accepted 
18%
33%
Days to publication 
18
145

Indexed in

Editor & editorial board
profiles
Academic society 
N/A

References

Zsigeti K and Lupsky JR. Charcot-Marie-Tooth disease.

Eur J Hum Genet 2009; 17: 703-710.

Palau F, Cuesta A, Pedrola L. Avances en la genética

molecular de las neuropatías hereditarias. Rev Neurol

; 35 (3): 246-253.

Banchs I, Casasnovas C, Alberti A, De Jorge L, Poveda-

no M, Montero J et al. Diagnosis of Charcot-Marie-Tooth

disease. J Biomed Biotechnol 2009; 2009: 985415. Epub

Oct 8.

Burgunder JM, Schöls L, Baets J, Andersen P, Gasser

T, Szolnoki Z et al. EFNS guidelines for the molecular

diagnosis of neurogenetic disorders: motoneuron, peri-

pheral nerve and muscle disorders. Eur J Neurol 2011;

(2): 207-217.

Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE,

Shy ME. Charcot-Marie-Tooth disease subtypes and

genetic testing strategies. Ann Neurol 2011; 69 (1): 22-33.

Newman CJ, Walsh M, O’Sullivan R, Jenkinson A,

Bennet D, Lynch B et al. The characteristics of gait in

Charcot-Marie-Tooth disease types I and II. Gait Posture

; 26 (1): 120-127.

Berciano J, Sevilla T, Casasnovas C, Sivera R, Vilchez

JJ, Infante J et al. Guía Diagnóstica en el paciente con

enfermedad de Charcot-Marie-Tooth. Neurologia 2011;

doi:10.1016/j.nrl.2011.04.015.

Patzcó A, Shy ME. Update on Charcot-Marie-Tooth

disease. Curr Neurol Neurosci Rep 2011; 11 (1): 78-88.

Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu

S, Maisonobe T et al. Charcot-Marie-Tooth disease type

A with 17p11.2 duplication. Clinical and electrophysio-

logical phenotype study and factors infl uencing disease

severity in 119 cases. Brain 1997; 120 (5): 813-823.

Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asa-

numa K, Jia-Ying S et al. Nerve excitability properties in

Charcot-Marie-Tooth disease type 1A. Brain 2004; 127

(Pt 1): 203-211.

Hanemann CO, D’Urso D, Gabreëls-Festen AA, Müller

HW. Mutation-dependent alteration in cellular distribution of

peripheral myelin protein 22 in nerve biopsies from Charcot-

Marie-Tooth type 1A. Brain 2000; 123 (Pt 5): 1001-1006.

D’Urso D, Prior R, Greiner-Petter R, Gabreëls-Festen

AA, Müller HW. Overloaded endoplasmic reticulum-Golgi

compartments, a possible pathomechanism of peripheral

neuropathies caused by mutations of the peripheral mye-

lin protein PMP22. J Neurosci 1998; 18 (2): 731-740.

Kochanski A. How to assess the pathogenicity of

mutations in Charcot-Marie-Tooth disease and other

diseases? J Appl Genet 2006; 47 (3): 255-260.

Dubourg O, Tardieu S, Birouk N, Gouider R, Léger JM,

Maisonobe T et al. Clinical, electrophysiological and mo-

lecular genetic characteristics of 93 patients with X-linked

Charcot-Marie-Tooth disease. Brain 2001; 124 (Pt 10):

-1967.

Gallardo E, García A, Combarros O, Berciano J. Char-

cot-Marie-Tooth disease type 1A duplication: spectrum

of clinical and magnetic resonance imaging features in

leg and foot muscles. Brain 2006; 129 (Pt 2): 426-437.

Chen SR, Lin KP, Kuo HC, Chen CM, Hsieh ST, Lee MJ

et al. Comparison of two PCR-based molecular methods

in the diagnosis of CMT 1A and HNPP diseases in Chi-

nese. Clin Neurol Neurosur 2008; 110 (5): 466-471.

Choi JR, Lee WH, Sunwoo IN, Lee EK, Lee CH, Lim JB.

Effectiveness of real-time quantitative PCR compare to

repeat PCR for the diagnosis of Charcot-Marie-Tooth

Type 1A and hereditary neuropathy with liability to

pressure palsies. Yonsei Med J 2005; 46 (3): 347-352.

Fischer C, Trajanoski S, Papić L, Windpassinger C, Ber-

nert G, Freilinger M et al. SNP array-based whole genome

homozygosity mapping as the fi rst step to a molecular

diagnosis in patients with Charcot-Marie-Tooth disease.

J Neurol 2011; doi:10.1007/s00415-011-6213-8.

Lorentzos P, Kaiser T, Kennerson ML, Nicholson GA. A

rapid and defi nitive test for Charcot-Marie-Tooth 1A and

hereditary neuropathy with liability to pressure palsies using

multiplexed real-time PCR. Genet Test 2003; 7 (2): 135-138.

Ruiz-Ponte C, Carracedo A, Barros F. Duplication and

deletion analysis by fl uorescent real-time PCR-based

genotyping. Clin Chim Acta 2006; 363 (1-2): 138-146.

Stangler-Herodez S, Zagradisnik B, Erjavec SA, Zagorac

A, Kokalj VN. Molecular diagnosis of PMP22 gene dupli-

cations and deletions: comparison of different methods.

J Int Med Res 2009; 37 (5): 1626-1631.

Burns J, Ramchandren S, Ryan MM, Shy M, Ouvrier

RA. Determinants of reduced health-related quality of

life in pediatric inherited neuropathies. Neurology 2010;

(8): 726-731.

Pareyson D, Reilly MM, Schenone A, Fabrizi GM,

Cavallaro T, Santoro L et al. Ascorbic acid in Charcot-

Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-

TRAUK): a double-blind randomized trial. Lancet Neurol

; 10 (4): 320-328.

Myers JK, Mobley CK, Sanders CR. The peripheral neu-

ropathy-linked Trembler and Trembler-J mutant forms

of peripheral myelin protein 22 are folding-destabilized.

Biochemistry 2008; 47 (40): 10620-10629.

Huxley C, Passage E, Robertson AM, Youl B, Huston

S, Manson A et al. Correlation between varying levels

of PMP22 expression and the degree of dysmyelination

and reduction in nerve conduction velocity in transgenic

mice. Hum Mol Genet 1998; 7 (3): 449-458.

Niemann S, Sereda MW, Rossner M, Stewart H, Suter

U, Minck HM et al. The “CMT rat”: peripheral neuropathy

and dysmyelination caused by transgenic overexpres-

sion of PMP22. Ann N Y Acad Sci 1999; 883: 254-261.

Niemann S, Sereda MW, Suter U, Griffi ths IR, Nave

KA. Uncoupling of myelin assembly and Schwann cell

differentiation by transgenic overexpression of peri-

pheral myelin protein 22. J Neurosci 2000; 20 (11):

-4128.

Published

2026-04-08

How to Cite

1.
Cortés Callejas H, Magaña Aguirre JJ, Hernández Hernández Óscar, Ávalos Fuentes JA, Recillas Morales S, Leyva García N. A look at Charcot-Marie-Tooth disease. Invest. Discapacidad [Internet]. 2026 Apr. 8 [cited 2026 Apr. 8];1(2):77-82. Available from: https://dsm.inr.gob.mx/indiscap/index.php/INDISCAP/article/view/957

Issue

Section

Evidence synthesis and meta-research

Most read articles by the same author(s)

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.